Cargando…

Expression of drug targets in primary and matched metastatic renal cell carcinoma tumors

BACKGROUND: Targeted therapies in renal cell carcinoma can have different effects on primary and metastatic tumors. To pave the way for predictive biomarker development, we assessed differences in expression of targets of currently approved drugs in matched primary and metastatic specimens from 34 p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Aziz, Saadia A, Sznol, Joshua A, Adeniran, Adebowale, Parisi, Fabio, Kluger, Yuval, Camp, Robert L, Kluger, Harriet M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3575219/ https://www.ncbi.nlm.nih.gov/pubmed/23374878 http://dx.doi.org/10.1186/1472-6890-13-3

Ejemplares similares

Vascularity of primary and metastatic renal cell carcinoma specimens
por: Aziz, Saadia A, et al.
Publicado: (2013)

MET Expression in Primary and Metastatic Clear Cell Renal Cell Carcinoma: Implications of Correlative Biomarker Assessment to MET Pathway Inhibitors
por: Shuch, Brian, et al.
Publicado: (2015)

Microvessel area as a predictor of sorafenib response in metastatic renal cell carcinoma
por: Aziz, Saadia A, et al.
Publicado: (2014)

Characterization of tumor infiltrating lymphocytes in paired primary and metastatic renal cell carcinoma specimens
por: Baine, Marina K., et al.
Publicado: (2015)

NY-ESO-1 as a potential immunotherapeutic target in renal cell carcinoma
por: Giesen, Eva, et al.
Publicado: (2014)

Coupled fibromodulin and SOX2 signaling as a critical regulator of metastatic outgrowth in melanoma
por: Oria, Victor O., et al.
Publicado: (2022)

Location matters: LAG3 levels are lower in renal cell carcinoma metastatic sites compared to primary tumors, and expression at metastatic sites only may have prognostic importance
por: Schoenfeld, David A., et al.
Publicado: (2022)

Benefits of biomarker selection and clinico-pathological covariate inclusion in breast cancer prognostic models
por: Parisi, Fabio, et al.
Publicado: (2010)

19. PLEKHA5 REGULATES TUMOR GROWTH IN METASTATIC MELANOMA
por: Oria, Victor, et al.
Publicado: (2020)

MEK targeting in N-RAS mutated metastatic melanoma
por: Thumar, Jaykumar, et al.
Publicado: (2014)

Melanoma brain metastases have lower T-cell content and microvessel density compared to matched extracranial metastases
por: Weiss, Sarah A., et al.
Publicado: (2020)

Immune dysfunction revealed by digital spatial profiling of immuno-oncology markers in progressive stages of renal cell carcinoma and in brain metastases
por: Schoenfeld, David A, et al.
Publicado: (2023)

Impact of healthcare worker shift scheduling on workforce preservation during the COVID-19 pandemic
por: Kluger, Dan M., et al.
Publicado: (2020)

Characterization and targeting of phosphatidylinositol-3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in renal cell cancer
por: Elfiky, Aymen A, et al.
Publicado: (2011)

VDA, a Method of Choosing a Better Algorithm with Fewer Validations
por: Strino, Francesco, et al.
Publicado: (2011)

Drug targets and predictive biomarkers in the management of metastatic melanoma
por: Thumar, Jaykumar, et al.
Publicado: (2012)

The X-linked inhibitor of apoptosis protein (XIAP) is up-regulated in metastatic melanoma, and XIAP cleavage by Phenoxodiol is associated with Carboplatin sensitization
por: Kluger, Harriet M, et al.
Publicado: (2007)

Characterizing disease states from topological properties of transcriptional regulatory networks
por: Tuck, David P, et al.
Publicado: (2006)

SIMVI reveals intrinsic and spatial-induced states in spatial omics data
por: Dong, Mingze, et al.
Publicado: (2023)

TrAp: a tree approach for fingerprinting subclonal tumor composition
por: Strino, Francesco, et al.
Publicado: (2013)

Expression patterns and prognostic value of Bag-1 and Bcl-2 in breast cancer
por: Nadler, Yasmine, et al.
Publicado: (2008)

PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF(WT) melanoma cells
por: Halaban, Ruth, et al.
Publicado: (2010)

Case report: Metastatic Merkel cell carcinoma presenting seven years after loco-regional disease resection of primary tumor with interval in-transit and nodal metastases
por: Rusheen, Joshua, et al.
Publicado: (2023)

Cardiac Biventricular Metastasis From Renal Cell Carcinoma
por: Latifi, Ahmad Nawid, et al.
Publicado: (2020)

Integrated Analysis of Tumor Samples Sheds Light on Tumor Heterogeneity
por: Parisi, Fabio, et al.
Publicado: (2012)

Survival after checkpoint inhibitors for metastatic acral, mucosal and uveal melanoma
por: Klemen, Nicholas D., et al.
Publicado: (2020)

PD-L1 Expression in Clear Cell Renal Cell Carcinoma: An Analysis of Nephrectomy and Sites of Metastases
por: Jilaveanu, L.B., et al.
Publicado: (2014)

Precipitation of Autoimmune Diabetes With Anti-PD-1 Immunotherapy
por: Hughes, Jing, et al.
Publicado: (2015)

Picking ChIP-seq peak detectors for analyzing chromatin modification experiments
por: Micsinai, Mariann, et al.
Publicado: (2012)

Arpeggio: harmonic compression of ChIP-seq data reveals protein-chromatin interaction signatures
por: Stanton, Kelly Patrick, et al.
Publicado: (2013)

Markers of inflammation are associated with clinical outcomes in patients with metastatic renal cell carcinoma treated with nivolumab
por: Sznol, Mario, et al.
Publicado: (2015)

A modified IL-18 drug in combination with CTLA-4 blockade enhances anti-tumor efficacy in preclinical models of renal cell carcinoma
por: Schoenfeld, David, et al.
Publicado: (2023)

Interactions with RNA direct the Polycomb group protein SCML2 to chromatin where it represses target genes
por: Bonasio, Roberto, et al.
Publicado: (2014)

Nuclear IRF-1 expression as a mechanism to assess “Capability” to express PD-L1 and response to PD-1 therapy in metastatic melanoma
por: Smithy, James W., et al.
Publicado: (2017)

Distinct immunologic changes in vivo following combination versus individual PD-1 or CTLA-4 checkpoint blockade in human cancer
por: Dhodapkar, Kavita, et al.
Publicado: (2014)

MET Inhibition in Clear Cell Renal Cell Carcinoma
por: Xie, Zuoquan, et al.
Publicado: (2016)

Expression of NKX3.1, Prostatic Specific Antigen and Prostatic Specific Alkaline Phosphatase in Cytology Specimens of Metastatic Prostatic Carcinoma
por: Wang, Minhua, et al.
Publicado: (2021)

Germline genetic variants are associated with development of insulin-dependent diabetes in cancer patients treated with immune checkpoint inhibitors
por: Caulfield, Jasmine I, et al.
Publicado: (2023)

Targeting Innate Immunity to Treat Cancer
por: Austin, Matthew, et al.
Publicado: (2020)

Longitudinal single-cell analysis of a patient receiving adoptive cell therapy reveals potential mechanisms of treatment failure
por: Qu, Rihao, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_jhlo8idht081aqmvhi8ok903he